利培酮治疗抽动秽语综合征临床资料分析

Analyses of clinical data of risperidone in Tourette syndrome

目的：探讨利培酮治疗抽动秽语综合征的临床疗效和安全性。方法将40例抽动秽语综合征患者随机分为两组，分别给予利培酮及氟哌啶醇治疗，观察6周。治疗前后采用耶鲁综合抽动严重性量表、副反应量表评定临床疗效及不良反应。结果治疗2周末起两组耶鲁综合抽动严重性量表总分均较治疗前显著降低（ P＜0．05或0．01），同期两组间比较差异无显著性（P＞0．05），治疗6周末两组临床疗效比较差异无显著性（P＞ 0．05）。利培酮组不良反应较轻微，副反应量表评分显著低于氟哌啶醇组（P＜0．01）。结论利培酮治疗抽动秽语综合征疗效显著，与氟哌啶醇相当，且安全性高，可作为治疗抽动秽语综合征的首选药物之一。

Objective To explore the efficacy and safety of risperidone in Tourette syndrome .Methods Forty patients with Tourette syndrome were randomly assigned to two groups treated with risperidone or haloperidol for 6 weeks .Before and after treatment efficacies were assessed with the Yale Global Tie Se‐verity Scale （YGTSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Re‐sults Since the end of the 2^nd week the YGTSS total scores of both groups lowered more significantly com‐pared with pretreatment （P〈0 .05 or 0 .01） ,those had no significant group differences （P〉0 .05） ,there was no significant group difference in efficacy at the end of the 6th week （P〉 0 .05） .Adverse reac‐tions were mild and the TESS score was significantly lower in risperidone than haloperidol group （P〈0 .01） . Conclusion Risperidone has an evident effect equivalent to haloperidol and higher safety in Tourette syndrome and could be used as choice drug .